Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica in vitro and in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 72-78

  Kurokawa, Masahiko ^a   Basnet, Purusotam ^a   Ohsugi, Mizue ^a   Hozumi, Toyoharu ^b   Kadota, Shigetoshi ^a   Namba, Tsuneo ^a   Kawana, Takashi ^c   Shiraki, Kimiyasu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Central Research and Development Laboratory   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; PHOSPHONOACETIC ACID; THYMIDINE KINASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CHROMATOGRAPHY; DRUG EFFECT; HERB; HERPES; HERPES SIMPLEX VIRUS; MEDICINAL PLANT; NONHUMAN; POISON IVY; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL TIME; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; BRAIN; ETHANOL; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, HUMAN; MICE; MICE, INBRED BALB C; OLEANOLIC ACID; PLANT EXTRACTS; PLANTS, TOXIC; PLAQUE ASSAY; SKIN; SOLVENTS; TOXICODENDRON;

EID: 0032892198     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ahsan M, Armstrong JA, Gray AI and Waterman PG (1995) Terpenoids, alkaloids and coumarins from Boronia inornata and Boronia gracilipes. Phytochemistry 38:1275-1278.
2. Birch CJ, Tachedjian G, Doherty RR, Hayes K and Gust ID (1990) Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis 162:731-734.
3. Dubbs DR and Kit S (1964) Mutant strains of herpes simplex virus deficient in thymidine kinase-inducing activity. Virology 22:493-502.
4. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, Gershon AA, Levy ML, Hayden GF, McGuirt PV, Harris J and Balfour HH Jr (1991) A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 325:1539-1544.
5. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant RM and Crumpacker CS (1989) Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 320:293-296.
6. Fiddian AP, Brigden D, Yeo JM and Hickmott EA (1984) Acyclovir: An update of the clinical applications of this antiherpes agent. Antiviral Res 4:99-117.
7. Gonalez AG, Amaro J, Fraga BM and Luis JG (1983) 3-Oxo-6β-hydroxyolean-18-en-28-oic acid from Orthopterygium huancuy. Photochemistry 22:1828-1830.
8. Hashimoto F, Kashiwada Y, Cosentino LM, Chen C-H, Garrett PE and Lee K-H (1997) Anti-AIDS agents: XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. Bioorg Med Chem 5:2133-2143.
9. Kishiwada Y, Hashimoto F, Cosentino LM, Chen C-H, Garrett PE and Lee K-H (1996) Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 39:1016-1017.
10. Kurokawa M, Hase K, Xu H-X, Yamamura J, Koyasu M, Satoh H. Kadota S, Hozumi T, Namba, T and Shiraki K (1993a) A novel procedure for the identification of a fraction with anti-herpes simplex virus type 1 activity in vivo from hot-water extract of traditional medicines, Geum Japonicum Thunb. J Med Pharm Soc WAKAN-YAKU 10:195-203.
11. Kurokawa M, Hozumi T, Basnet P, Nakano M, Kadota S, Namba T, Kawana, T and Shiraki K (1998) Purification and characterization of eugeniin as an anti-herpes virus compound from Geum japonicum and Svzygium aromaticum. J Pharmacol Exp Ther 284:728-735.
12. Kurokawa M, Nagasaka K, Hirabayashi T, Uyama S, Sato H, Kageyama T, Kadota S, Ohyama H, Hozumi T, Namba T and Shiraki K (1995a) Efficacy of traditional herb medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo. Antiviral Res 27:19-37.
13. Kurokawa M, Nakano M, Ohyama H, Hozumi T, Namba T and Shiraki K (1997) Prophylactic efficacy of traditional herbal medicines against recurrent herpes simplex virus type 1 infection from latently infected ganglia in mice. J Dermatol Sci 14:76-84.
14. Kurokawa M, Ochiai H, Nagasaka K, Neki M, Xu H, Kadota S, Sutardjo S, Matsumoto T, Namba T and Shiraki K (1993b) Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res 22:175-188.
15. Kurokawa M, Ohyama H, Hozumi T, Namba T, Nakano M and Shiraki K (1996) Assay for antiviral activity of herbal extracts using their absorbed sera. Chem Pharm Bull 44:1270-1272.
16. Kurokawa M, Sato H, Ohyama H, Hozumi T, Namba T, Kawana T and Shiraki K (1995b) Effects of traditional herb medicines against herpes simplex virus (HSV) type 2 and acyclovir-resistant HSV type 1 in vitro and in vivo. J Tradit Med 12:187-194.
17. Labrosse B, Pleskoff O, Sol N, Jones C, Henin Y and Alizon M (1998) Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. J Virol 71:8230-8236.
18. Majumder PL, Maiti RN, Panda SK and Mal D (1979) Structure of moronic acid. J Org Chem 44:2811-2812.
19. Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, Durack DT, Levin MJ, Segreti AC and Balfour HH (1982) Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 73:229-235.
20. Nakano M, Kurokawa M, Hozumi T, Saito A, Ida M, Morohashi M, Namba T, Kawana T and Shiraki K (1998) Suppression of recurrent genital herpes simplex virus type 2 infection by Rhus javanica in guinea pigs. Antiviral Res 39:25-33.
21. Norris SA, Kessler HA and Fife KH (1988) Severe progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis 157: 209-210.
22. Nugier F, Colin JN, Aymard M and Langlois M (1992) Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: Report on a two-year sensitivity screening survey. J Med Virol 36:1-12.
23. Oliver NM, Collins P, Van der Meer J and Van't Wout JW (1989) Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir. Antimicrob Agents and Chemother 33:635-640.
24. Pass RF, Whitley RJ, Whelchel JD, Diethelm AG, Reynolds DW and Alford CA (1979) Identification of patients with increased risk of infection with herpes simplex virus after renal transplantation. J Infect Dis 140:487-492.
25. Reusser P, Cordonnier C, Einsele H, Engelhard D, Link H, Locasciulli A, Ljungman P for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (1996) European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 17:813-817.
26. Sibrack CD, Gutman LT, Wilfert CM, McLaren C, St Clair MH, Keller PM and Barry DW (1982) Pathogenicity of acydovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 146-673-682.
27. Soler F, Poujade C, Evers M, Carry J-C, Henin Y, Bousseau A, Huet T, Pauwels R, De Clercq E, Mayaux J-F, Le Pecq J-B and Cereu N (1996) Betulinic acid derivatives: A new class of specific inhibitors of human immunodeficiency virus type 1 entry. J Med Chem 39:1069-1083.
28. Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, Jacobs R, Nahmias A, Soong S-J and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (1991) A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med 324:444-449.